Onglyza(saxagliptin)
Komboglyze, Onglyza, Qtern, Qternmet, Qtrilmet, Saxagliptin (saxagliptin) is a small molecule pharmaceutical. Saxagliptin was first approved as Onglyza on 2009-07-31. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat diabetes mellitus, glucose metabolism disorders, metabolic diseases, nutritional and metabolic diseases, and type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Combinations
Qtern (generic drugs available since 2023-07-31, discontinued: Kombiglyze, Qternmet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dapagliflozin
+
Metformin hydrochloride
+
Saxagliptin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QTERNMET XR | AstraZeneca | N-210874 DISCN | 2019-05-02 | 4 products, RLD |
Hide discontinued
Dapagliflozin
+
Saxagliptin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QTERN | AstraZeneca | N-209091 RX | 2017-02-27 | 2 products, RLD, RS |
Metformin hydrochloride
+
Saxagliptin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KOMBIGLYZE XR | AstraZeneca | N-200678 DISCN | 2010-11-05 | 3 products, RLD |
Hide discontinued
Saxagliptin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ONGLYZA | AstraZeneca | N-022350 DISCN | 2009-07-31 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| qtern | New Drug Application | 2023-09-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SAXAGLIPTIN HYDROCHLORIDE, SAXAGLIPTIN, AMNEAL | |||
| 2024-01-27 | PC | ||
SAXAGLIPTIN HYDROCHLORIDE, SAXAGLIPTIN, AUROBINDO PHARMA | |||
| 2024-01-27 | PC | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Dapagliflozin / Metformin Hydrochloride / Saxagliptin Hydrochloride, Qternmet Xr, Astrazeneca Ab | |||
| 9616028 | 2030-11-12 | DP | |
| 7919598 | 2029-12-16 | DP | |
| 8716251 | 2028-03-21 | DP | |
| 8501698 | 2027-06-20 | DP | U-493, U-1976, U-1977 |
| 6515117 | 2025-10-04 | DS, DP | U-493 |
| 8628799 | 2025-07-13 | DP | |
| Saxagliptin Hydrochloride, Onglyza, Astrazeneca Ab | |||
| 7951400 | 2028-11-30 | DP | |
| Dapagliflozin / Saxagliptin Hydrochloride, Qtern, Astrazeneca Ab | |||
| 8221786 | 2028-03-21 | DP | |
| 8361972 | 2028-03-21 | U-493, U-1976, U-1977 | |
| Metformin Hydrochloride / Saxagliptin Hydrochloride, Kombiglyze Xr, Astrazeneca Ab | |||
| 9339472 | 2025-07-13 | DP | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD10: Metformin and saxagliptin
— A10BD21: Saxagliptin and dapagliflozin
— A10BD25: Metformin, saxagliptin and dapagliflozin
— A10BH: Dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering
— A10BH03: Saxagliptin
HCPCS
No data
Clinical
Clinical Trials
153 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 16 | 5 | 33 | 32 | 34 | 119 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | 3 | 2 | 5 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | 3 | 1 | 4 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 2 | — | — | 2 | — | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | 1 | 2 | — | 4 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | 1 | 1 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 3 | — | 3 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | 2 | — | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | 1 | — | — | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | 1 | — | — | 1 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fragile x syndrome | D005600 | — | Q99.2 | 1 | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | HP_0000855 | E88.819 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise | D015444 | EFO_0000483 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 2 | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 1 | 1 |
| Diabetic ketoacidosis | D016883 | EFO_1000897 | — | — | — | — | — | 1 | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 1 | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 1 | 1 |
| Endoplasmic reticulum stress | D059865 | EFO_1001886 | — | — | — | — | — | 1 | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Saxagliptin |
| INN | saxagliptin |
| Description | Saxagliptin is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2S)-amino(3-hydroxyadamantan-1-yl)acetic acid with the amino group of (1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carbonitrile. Used in its monohydrate form for the treatment of Type II diabetes. It has a role as a hypoglycemic agent and an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor. It is a member of adamantanes, a nitrile, an azabicycloalkane, a tertiary alcohol and a monocarboxylic acid amide. |
| Classification | Small molecule |
| Drug class | dipeptidyl aminopeptidase-IV inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O |
Identifiers
| PDB | — |
| CAS-ID | 945667-22-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103745 |
| ChEBI ID | 71271 |
| PubChem CID | 11243969 |
| DrugBank | DB06335 |
| UNII ID | 8I7IO46IVQ (ChemIDplus, GSRS) |
Target
Agency Approved
DPP4
DPP4
Organism
Homo sapiens
Gene name
DPP4
Gene synonyms
ADCP2, CD26
NCBI Gene ID
Protein name
dipeptidyl peptidase 4
Protein synonyms
ADABP, ADCP-2, Adenosine deaminase complexing protein 2, CD26, Dipeptidyl peptidase IV, dipeptidylpeptidase 4, dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2), DPP IV, Gly-Pro naphthylamidase, Post-proline dipeptidyl aminopeptidase IV, T-cell activation antigen CD26, TP103, Xaa-Pro-dipeptidylaminopeptidase
Uniprot ID
Mouse ortholog
Dpp4 (13482)
dipeptidyl peptidase 4 (Q3U514)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Onglyza – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Onglyza – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Qtern – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Saxagliptin
+
Metformin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Saxagliptin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,478 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,531 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use